Stroke Trial, Recruiting (NCT06519292)

Stroke Trial, Recruiting NCT06519292 Sponsor: Hanneke W. M. van Laarhoven Condition: Stroke

Printed from Voxsanity (voxsanity.com.au) — NCT06519292 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Stroke

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with one of the following cancers (at any stage): esophageal cancer, stomach cancer, cancer at the junction between the esophagus and stomach, colorectal cancer, non-small cell lung cancer, melanoma, or kidney cancer
You are about to start a new treatment (such as immunotherapy or chemotherapy) or, if you have esophageal cancer, are about to begin a follow-up period — meaning you have not yet started this new phase of care
You are 50 years of age or older

Who may not be able to join:

You have received immunotherapy (specifically immune checkpoint inhibitor therapy) within the last 12 months
You have a suspected or confirmed infection, whether viral, fungal, or bacterial
You are currently taking medications that suppress the immune system prior to starting immunotherapy
Your kidneys are not functioning well enough, based on a specific blood test measurement (confirm with trial site)
You have a known allergy to the type of dye used in certain medical scans (called iodinated contrast agents)
You have a heart condition called atrial fibrillation (an irregular heartbeat)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: H.W.M. van Laarhoven, Prof. Dr., secretariaat.oncologie@amsterdamumc.nl

Phone: +31 205665975

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06519292

Sponsor: Hanneke W. M. van Laarhoven

Phase: Not Applicable

Status: Recruiting

Condition: Stroke

Trial contact: +31 205665975

More information: https://clinicaltrials.gov/study/NCT06519292

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with one of the following cancers (at any stage): esophageal cancer, stomach cancer, cancer at the junction between the esophagus and stomach, colorectal cancer, non-small cell lung cancer, melanoma, or kidney cancer
You are about to start a new treatment (such as immunotherapy or chemotherapy) or, if you have esophageal cancer, are about to begin a follow-up period — meaning you have not yet started this new phase of care
You are 50 years of age or older

Who may not be able to join:

You have received immunotherapy (specifically immune checkpoint inhibitor therapy) within the last 12 months
You have a suspected or confirmed infection, whether viral, fungal, or bacterial
You are currently taking medications that suppress the immune system prior to starting immunotherapy
Your kidneys are not functioning well enough, based on a specific blood test measurement (confirm with trial site)
You have a known allergy to the type of dye used in certain medical scans (called iodinated contrast agents)
You have a heart condition called atrial fibrillation (an irregular heartbeat)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Hanneke W. M. van Laarhoven

Registry

ClinicalTrials.gov

Start date

25 January 2023

Est. completion

31 December 2025

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Non-calcified coronary plaque volume (difference between baseline and follow-up CT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov